Clinical trial
A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence
NCT03194542 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence
- Lead sponsor
- Celgene
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 15, 2017
- Completion date
- July 18, 2022
- Enrollment
- 95 (actual)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.